Innovent Says Takeda Wins Japan SAKIGAKE Designation for Gastric Cancer Drug Arcotatug Tavatecan
- Innovent Biologics announced Nov. 17, 2026, that Takeda received Japan's SAKIGAKE designation for arcotatug tavatecan (IBI343/TAK-921).
- The proposed indication covers CLDN18.2-positive unresectable advanced or recurrent gastric or gastroesophageal junction adenocarcinoma progressing after chemotherapy.
- The designation provides eligibility for priority regulatory consultation and priority review in Japan.
- The supporting Phase 3 G-HOPE-001 trial demonstrated meaningful survival benefits, delayed disease progression and a superior safety profile.
- Results from the trial, conducted in China and Japan, were already presented at the 2026 European Society for Medical Oncology Congress.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.